(Q34706872)

English

A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control: advantages of pathway-based discovery (English)

1 reference

Europe PubMed Central

4 August 2017

1 reference

based on heuristic

inferred from title

Marc Hellerstein

1

object named as

Marc K Hellerstein

1 reference

Europe PubMed Central

4 August 2017

publication date

20 September 2007

1 reference

Europe PubMed Central

4 August 2017

Metabolic Engineering

1 reference

Europe PubMed Central

4 August 2017

10

1 reference

Europe PubMed Central

4 August 2017

1-9

1 reference

Europe PubMed Central

4 August 2017

1

1 reference

Europe PubMed Central

4 August 2017

Lessons from metabolic engineering for functional genomics and drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Reflections on the scope and the future of metabolic engineering and its connections to functional genomics and drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Drug discovery in the wake of genomics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

The agony and ecstasy of "OMIC" technologies in drug development

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Genetic information, genomic technologies, and the future of drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

The impact of genomics on drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Attrition and Translation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Cholesteryl ester transfer protein: friend or foe?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Large-scale in vivo flux analysis shows rigidity and suboptimal performance of Bacillus subtilis metabolism

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

The impact of systems approaches on biological problems in drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Genetic dissection of complex traits

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Effect of torcetrapib on the progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

From genes to whole organs: connecting biochemistry to physiology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Will genomics revolutionise pharmaceutical R&D?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Sickle cell anemia, a molecular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Modeling isotopomer distributions in biochemical networks using isotopomer mapping matrices

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Discovery of novel hippocampal neurogenic agents by using an in vivo stable isotope labeling technique.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Measurement of brain microglial proliferation rates in vivo in response to neuroinflammatory stimuli: application to drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Network rigidity and metabolic engineering in metabolite overproduction.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Exploiting biological complexity for strain improvement through systems biology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMBEN.2007.09.003

7 January 2021

Identifiers

10.1016/J.YMBEN.2007.09.003

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34706872&oldid=1979606457"